Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. - Wikidata - wikimedia - TriplyDB

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

http://www.wikidata.org/entity/Q33503017

about

Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.The cytoskeleton of digestive epithelia in health and disease.Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin.Hepatocellular carcinoma--cause, treatment and metastasis.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Hepatocellular carcinoma: are we making progress?Treatment of hepatocarcinoma.Systemic therapies for hepatocellular carcinoma.Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer.Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice Dose adaptation of antineoplastic drugs in patients with liver disease.Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel.Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway.Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro Systemic therapy in hepatocellular carcinoma.Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Atypical regulators of Wnt/β-catenin signaling as potential therapeutic targets in Hepatocellular Carcinoma.Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells.Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.Effects of paclitaxel and doxorubicin in histocultures of hepatocelular carcinomas.Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology.In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol Paclitaxel: a hope for advanced non-small cell lung cancer?Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

P2860

Q30965534-0D49DBB4-8C38-4BC9-A26A-C8ADDF36CD19 Q33333673-D9C55499-8E74-469A-976D-8853F5BC3913 Q33343204-093FE8DD-6AF7-4C47-B5AE-F1920FB263A7 Q33358104-90C438B4-39EF-4ED0-938A-EEBA88FAECCC Q33374394-6E91EC8D-7437-44C3-80F3-41AC159F48F1 Q33378906-D356BDD9-89B2-45E8-8854-91E28A4C3D6A Q33796503-4C9E2889-BAA8-45CE-A588-AB06AFBE20FF Q33866286-43F82B0B-F38B-47BA-BBFC-69DBFEBCF481 Q34512068-78ECD249-9C98-4F9C-930C-9993759D829D Q34632966-1FC17C68-CA8F-42DD-AA09-B6767548FB52 Q35193283-F3447745-A036-49D7-BC10-72851A2D99DA Q35739061-A4F98284-FD41-413A-A856-F6842F93868E Q35964708-537C24DC-F742-4E5D-8FD8-2A256187D811 Q36178201-0C3AA525-2063-4EAF-BD7E-C2E8B36D143C Q36297024-1F270D4A-0EF0-47BE-8D77-CC9AF92942B7 Q36491877-D012A696-5E10-496E-89D2-67E46B26F9E3 Q36497053-A0C346E7-1817-4BF3-980D-1DA4F8CE260F Q36619759-CC8CB47E-B92C-4EC6-9607-CB58F5692D5D Q36621462-936A503C-C833-4FAD-A3EC-E654AC3259C8 Q36648809-068706E3-B7DF-4A75-A05C-370C78D24DD2 Q36671639-7434096D-52F0-4724-B0A1-B176C05CFC46 Q36673674-1CE45FF5-089E-41A4-BFB4-148867A8DA32 Q36965059-7F47A91A-AF6B-4B49-8D2F-BF77F7129C22 Q37135733-DB8C916F-46D5-4DE3-B267-533D849941F6 Q37276117-6AA489B7-1E49-4873-8A96-BFE8C59C7918 Q37722656-33897AA8-6E3A-455A-98EE-E64231D9C255 Q37828640-D36FC465-A44B-4CB1-9EF4-39D24230F1F5 Q38726616-EED97B53-79AF-4F31-AC14-37B81D6E045D Q39254272-7BA9DE2E-7042-4849-AEB8-CC4AAA0255AA Q39882641-C1B3B819-2BE9-4C7F-B14E-0B29B895C366 Q40100660-EC757F4F-7825-4B19-8ADF-0FF47E6C503E Q40101788-882799B3-B816-4343-8797-FCCB1EC3063A Q40186181-4FB7D28A-1BAA-418F-BAF4-B377D52F2B2C Q41830340-2121772A-9E7C-4D9D-AA7C-B4633D9B097C Q41967143-9B67F5B3-3F72-4AE3-8ED6-0876C79B66E8 Q47614742-4BE98139-EAF6-4494-9EBE-F9D6A4D9D910 Q47664432-8A7F7300-9256-4625-8BC6-FC9062E9F63A Q58211591-EF89195C-F6EC-475E-9AC8-F6A914CEC93C

P2860

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

http://www.wikidata.org/entity/Q33503017

description

1998 nî lūn-bûn

@nan

1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@ast

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@en

type

label

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@ast

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@en

prefLabel

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@ast

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@en

P1433

Q33503017-0FF47ED3-0365-4C17-B279-F002F6B3B1EF

P1476

Q33503017-AFC1402E-5AE3-49A7-A04C-31E01984E14C

P2093

Q33503017-60CD7CAA-07F0-48AA-B2C4-37A757C5168B

Q33503017-7F96B53B-DDA7-41BC-B0A0-250A0E7CE6F1

Q33503017-8BC7BC8C-7350-4C07-B800-503CF58712EC

Q33503017-958BE4AD-15BE-415A-B37A-24623F91A1DD

Q33503017-95FF4953-1BD4-4EED-99D7-516569CCC97F

Q33503017-D29C7302-2485-47BB-883C-5A2C1A0BABF2

Q33503017-D8D51401-6DF1-43B0-B113-03815424ED06

Q33503017-DA131F13-5E17-4A68-BAF5-25B029DCB1D1

Q33503017-F3601503-AECE-4578-99D2-FFB6777AB489

Q33503017-FC8F531B-D895-439A-B8BC-6008D986CE24

P2860

Q33503017-0EBDAAF1-E151-45D2-9E3D-BCF6291850DC

Q33503017-2BD0EE0E-C631-4ED9-90FB-E3A86E1E639D

Q33503017-5193F2C2-882C-4D77-A906-DC90EB6207D7

Q33503017-524D4D24-98BB-44BC-A62D-44D10FC102C0

Q33503017-80A9D941-942C-4C7F-AF44-ECDF66768C1B

Q33503017-8C1460E8-DA53-4C6F-9EE3-90105BE48F98

Q33503017-A2350ED2-2D23-49E2-BE13-86F2C9E6179E

Q33503017-A91991E5-E33F-4860-9C79-26D5A3D1CA32

Q33503017-B3F36C8A-F9D2-4FB9-97C1-459D57894EBD

Q33503017-E6CDCC55-F987-4C8B-91A4-8F4A44FA3010

P2888

Q33503017-E08D55BA-E215-43BA-AF59-00FC8B83BA6C

P304

Q33503017-64D7918F-EE89-46F6-AF05-9CB195B90DF5

P31

Q33503017-E11194A9-CA9A-4064-9D79-9BE750BD9F76

P356

Q33503017-539F1476-0D8B-4FCC-AE58-63F9DFE69438

P407

Q33503017-C6BBC237-72DA-4F41-8CA1-2C279C87E235

P433

Q33503017-19882BB6-6EC5-4E85-872A-35EDADD34B6F

P478

Q33503017-A3E02B10-8C7C-4B4A-AC4E-4243E5701F16

P577

Q33503017-B08230D6-A5E1-4E15-B9EE-8B374D9E3807

P5875

Q33503017-ECAD5C2A-08A7-4FB4-9F99-B5089F7ED3CE

P6179

Q33503017-D19A64BF-47E7-49F8-9F37-7A5CE7E8AFB4

P698

Q33503017-8941840F-88AA-49E0-BF06-928124A1E7AF

P932

Q33503017-B12E3E4F-40EE-44CB-A997-6BA027D093DF

P356

P1433

British Journal of Cancer

P1476

Phase II and pharmacokinetic s ...... tocellular carcinoma patients.

@en

P2093

Birkhofer MJ

http://www.w3.org/2001/XMLSchema#string

Chan WK

http://www.w3.org/2001/XMLSchema#string

Chao Y

http://www.w3.org/2001/XMLSchema#string

Chi KH

http://www.w3.org/2001/XMLSchema#string

Hu OY

http://www.w3.org/2001/XMLSchema#string

Huang YS

http://www.w3.org/2001/XMLSchema#string

Lee SD

http://www.w3.org/2001/XMLSchema#string

Liu M

http://www.w3.org/2001/XMLSchema#string

Lui WY

http://www.w3.org/2001/XMLSchema#string

Wang SS

http://www.w3.org/2001/XMLSchema#string

P2860

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.

Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction.

Taxol: pharmacology, metabolism and clinical implications.

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.

Taxol: mechanisms of action and resistance.

Clinical toxicities encountered with paclitaxel (Taxol).

Treatment of hepatocellular carcinoma: too many options?

Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection.

Optimal two-stage designs for phase II clinical trials.

P2888

P304

34-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1998.438

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

1998-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13623123

http://www.w3.org/2001/XMLSchema#string

P6179

1039075669

http://www.w3.org/2001/XMLSchema#string

P698

9662247

http://www.w3.org/2001/XMLSchema#string

P932

2062942

http://www.w3.org/2001/XMLSchema#string